With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...

For some diseases, gene therapies offer the potential for lifelong disease amelioration and even cure. And these immensely important novel biotechnologies may be on the cusp of a boom. That is in part ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has ...

Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FDA approval for their gene-editing therapy Casgevy (exa-cel) to treat transfusion-dependent beta thalassemia (TDT). The approval comes ...

Global clinical-stage biotech company HuidaGene Therapeutics has received FDA clearance to move forward with its application for its investigational drug, a CRISPR/Cas13 RNA-editing therapy to treat ...

KJ Muldoon recently made history by becoming the first patient to receive a personalized CRISPR gene therapy, designed specifically for the genetic mutations causing his rare metabolic disease. Now, a ...

CRISPR Therapeutics now has an approved product in its portfolio in Casgevy. The treatment has the potential to be a game changer for the company's business. Even with more treatments in its portfolio ...

Genome editing technologies like CRISPR-Cas9 have transformed biology, medicine, and agriculture, but concerns remain about unintended edits at off-target DNA sites. These off-target effects can cause ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...